These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 28406477

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 3. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL.
    Mol Metab; 2017 Nov 14; 6(11):1360-1370. PubMed ID: 29107284
    [Abstract] [Full Text] [Related]

  • 4. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.
    PLoS One; 2024 Nov 14; 19(4):e0300809. PubMed ID: 38662778
    [Abstract] [Full Text] [Related]

  • 5. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
    van den Hoek AM, Verschuren L, Worms N, van Nieuwkoop A, de Ruiter C, Attema J, Menke AL, Caspers MPM, Radhakrishnan S, Salic K, Kleemann R.
    Cells; 2020 Sep 01; 9(9):. PubMed ID: 32883049
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.
    Gastroenterology; 2013 Sep 01; 145(3):574-82.e1. PubMed ID: 23727264
    [Abstract] [Full Text] [Related]

  • 7. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
    J Hepatol; 2016 May 01; 64(5):1158-1166. PubMed ID: 26812075
    [Abstract] [Full Text] [Related]

  • 8. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L, Pruzanski M, Shapiro D.
    Drug Discov Today; 2012 Sep 01; 17(17-18):988-97. PubMed ID: 22652341
    [Abstract] [Full Text] [Related]

  • 9. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, Asakawa M, Yoneyama T, Kai T, Ogawa Y.
    Sci Rep; 2018 May 25; 8(1):8157. PubMed ID: 29802399
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W.
    Korean J Gastroenterol; 2017 Jun 25; 69(6):353-358. PubMed ID: 28637104
    [Abstract] [Full Text] [Related]

  • 12. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.
    Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M.
    World J Gastroenterol; 2018 Jan 14; 24(2):195-210. PubMed ID: 29375205
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J, Liu C, Zhou Z, Dou B, Huang J, Huang L, Zheng P, Fan S, Huang C.
    Phytother Res; 2021 Jun 14; 35(6):3351-3364. PubMed ID: 33784797
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
    Shah RA, Kowdley KV.
    Expert Rev Gastroenterol Hepatol; 2020 May 14; 14(5):311-321. PubMed ID: 32241197
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.